A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Psoriasis

Study type: Observational

Funder types: Industry

Identifiers

NCT05633264

IM011-226

Details and patient eligibility

About

The purpose of this study is to determine the safety and effectiveness of deucravacitinib for the treatment of plaque psoriasis (PsO) in Japan participants.

Enrollment: 369 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Psoriasis (PsO) participants who received Deucravacitinib for the first time of the approved indications at medical institutions in Japan will be enrolled in this PMS

Exclusion criteria

• Participants receiving Deucravacitinib for an off-label indication will be excluded from this PMS.

Trial design

369 participants in 1 patient group

Cohort 1

Description:

Psoriasis (PsO) participants who initiate treatment with Deucravacitinib.